Dynamic 3D <i>in vitro</i> lung models: applications of inorganic nanoparticles for model development and characterization-Reference-Cited by-同舟云学术

Dynamic 3D in vitro lung models: applications of inorganic nanoparticles for model development and characterization

Published:2024 Issue:23 Volume:16 Page:10880-10900
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Fallert Laura¹²³,Urigoitia-Asua Ane¹³⁴,Cipitria Amaia²⁵^ORCID,Jimenez de Aberasturi Dorleta¹⁵⁶^ORCID

Affiliation:

1. Department of Hybrid Biofunctional Materials, CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo de Miramon 194, 20014 Donostia-San Sebastián, Spain

2. Group of Bioengineering in Regeneration and Cancer, Biogipuzkoa Health Research Institute, 20014 Donostia-San Sebastián, Spain

3. Department of Applied Chemistry, University of the Basque Country, 20018 Donostia-San Sebastián, Spain

4. POLYMAT, Basque Centre for Macromolecular Design and Engineering, 20018 Donostia-San Sebastián, Spain

5. Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain

6. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, ISCIII), 20014 Donostia-San Sebastián, Spain

Abstract

In this review, the authors elaborate on the most recent advances of lung in vitro models and inform on the potential of nanoparticles as a means to create dynamic models as well as nanoparticle-based characterization strategies.

Funder

Ministerio de Ciencia e Innovación

Eusko Jaurlaritza

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NR/D3NR06672J

Reference208 articles.

1. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

2. Biomaterial inks and bioinks for fabricating 3D biomimetic lung tissue: A delicate balancing act between biocompatibility and mechanical printability

3. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning

4. Barriers to new drug development in respiratory disease

5. Phase II and Phase III attrition rates 2011–2012